3D 細胞培養：各種技術與全球市場

全球3D細胞培養市場規模預計將從2023年的46億美元成長到2028年的148億美元，預測期內複合年成長率為26.5%。

從應用來看，研究市場預計將從2023年的23億美元成長到2028年的78億美元，複合年成長率為27.3%。此外，生物加工市場預計將從2023年的22億美元成長到2028年的近70億美元，複合年成長率為25.7%。

本報告調查了全球3D細胞培養市場，並提供了該技術的發展過程、類型和概述、應用、研發趨勢、市場規模趨勢和預測、各個細分市場和地區的詳細分析、競爭形勢和主要A集合等資訊。主要企業簡介等

目錄

第1章簡介

第 2 章摘要/亮點

• 市場展望
• 市場摘要

第3章市場概況

• 關於一個偉大行業的開放評論
• 工業問題
• 體外和體內
• 維數
• 2D和3D細胞培養研究鏈
• 最佳實踐
• 標準化
• 規定
• FDA 和基因組學
• 浸出物和萃取物
• 普遍存在的問題
• 缺乏研究人力資源
• 國際形勢變化
• 創新的步伐和多樣化
• 對細胞培養「其他」領域的評論
• 無論位置如何，體學
• 2020年會是細胞培養產業的分水嶺年嗎？
• 初步市場分析
• 細胞培養市場成長率估算
• 評估大規模媒體消費需求
• 模擬生物製藥的未來成長
• 細胞培養市場基本案例
• 預測銷售和成長的挑戰
• 細胞培養基市場預測
• 細胞和基因治療生物生物製程的分類
• 生物相似藥介質消耗的評估
• CDMO
• 微流體學
• 生物反應器
• 內部細胞培養資源
• 生物技術領域的所有權集中
• 3D細胞培養的創新特點
• 生物列印戰略藍圖

第4章市場類型

• 組織和細胞培養的起源
• 歷史和早期應用
• 組織培養的發明
• 持久性細胞株的開發
• 第一個細胞培養瓶和嚴格的技術
• Lindbergh：細胞培養設備的先驅
• 連續細胞株的建立
• 裝備主要發展
• 術語和概念
• 組織和細胞培養產業
• 組織培養和細胞培養的定義
• 細胞株
• 細胞培養系統的維護與擴展
• 培養基、血清、試劑
• 凝膠和支架
• 微孔板/微量滴定板
• 生物分析設備
• 生物分析成像
• 生物列印
• 生物反應器
• 其他細胞培養設備
• 黏合黏合
• 傳統滾瓶
• 其他系統
• IT：細胞培養研究市場的軟體與服務
• 細胞培養研究市場軟體
• 軟體相關支援服務
• 用於細胞培養的生物製程耗材
• 用於大規模 3D 培養的微載體
• 用於大規模 3D 培養的血清
• 大型3D培養基
• 用於大規模 3D 培養的生物反應器袋
• 其他
• 製程設備
• 生物過程分析儀
• 生物製程自動化系統
• 生物製程支援設備
• 生物製藥和疫苗規模化生產的方面
• 懸浮蛋白和單株抗體
• 以貼壁細胞為基礎的治療方法和疫苗
• 用於創建體細胞、幹細胞和組織的小型黏劑
• 疫苗
• 疫苗開發作為催化劑
• 使用人類細胞株開發的疫苗
• 胞外體生產
• 病毒載體生產
• 慢病毒生產
• 質體生產
• 細胞培養最終用戶
• 製藥/生物製藥
• 大學
• 政府
• CRO/CDMOS
• 其他
• 細胞培養應用
• 藥物研發
• 臨床開發
• 毒理學
• 基礎研究
• 生物製程開發
• 其他
• 區域市場
• 美洲
• 歐洲
• 亞太地區
• 其他地區

第 5 章 測定/成像/分析

• 化驗
• 間質幹細胞檢測開發
• 外來性病原體的體外檢測
• 測定及測定套件
• 基於細胞的檢測：概述和新進展
• 用於基於細胞的測定的細胞
• 基於 3D 細胞的檢測的註釋
• 動力學代謝測定
• 細胞增殖
• 能源和細胞毒性
• 細胞活力和活力滲透性測定
• 細胞侵襲
• 細胞訊號傳導和通訊
• 細胞抑制特性
• 細胞死亡化驗
• 成像技術
• 影像分析
• 螢光作為篩檢促進因素
• 用於組織和細胞培養的分析系統
• 了解“ CELLOMICS”
• 支持 HCS 的 3D 細胞培養
• NGS 探索池
• 多重分析
• 預測毒理學
• 神經安全
• 體學的入侵
• 轉錄組學

第6章 法規/標準化

• 美國生物列印產品的監管狀況
• 生技藥品監管基本指南
• 再生醫學指導
• 異種移植指南
• 再生醫學指引：緊急核准
• 生物列印產品的監管

第7章癌症的3D模型

• 疾病建模
• 癌症
• 研究癌症和其他疾病的主要模型類別
• 細胞株
• 球體和類器官
• 基因工程小鼠模型（GEMM）
• 患者來源的腫瘤異質骨移植（PDX）
• 概述：細胞層面的癌症
• 體內（動物）測試標準
• 滑鼠帝國
• 人源化小鼠
• QR 圖文化
• 3D要求
• 細胞數量和活力
• 遷徙和入侵
• 未滿足的需求：血管新生和免疫系統逃脫
• 3D 模型在癌症研究的優勢
• 細胞型態和增殖的優異分化
• 改善基因表現和細胞行為
• 更好的細胞遷移與侵襲模型
• 細胞異質性
• 乳癌作為 3D 文化的驅動力
• 結構、極性、細胞凋亡
• 黑色素瘤作為 3D 文化的驅動力
• 遷移到球體配置
• 癌症研究中的 3D 系統
• 多細胞腫瘤球體
• 多層細胞培養
• 3D設計鷹架
• 天然材質
• 合成材料
• 人類癌症模型舉措(HCMI)
• 下一代人類癌症模型
• 藥物敏感性和抗藥性
• 訊號傳導和敏感性的變化
• 抗藥性
• 細胞訊號傳導
• 透過整合素的細胞訊號傳導
• 藥物篩檢
• 方法和終點
• 球體的用途
• 使用 3D 細胞遷移模型進行轉移
• 透過晶片肺轉移
• 癌症代謝
• 未來地平線
• 轉移
• 共培養
• 血管新生
• 癌症相關纖維母細胞
• 癌症幹細胞
• 聯合治療
• 生技藥品開發
• 腫瘤復發
• 患者來源的細胞
• 患者來源的腫瘤異質骨移植（PDX）
• PDX 平台的演變

第8章毒理學和藥物安全性檢測形勢

• 肝
• 有毒背景
• 皮膚副作用測試
• 新評估方法對 3D 細胞培養的影響
• 化妝品毒性測試
• 更新的監管要求
• 化妝品和藥妝品的功效
• 化妝品毒性測試的方面
• 皮膚發炎
• 皮膚腐蝕
• 光毒性
• 皮膚過敏
• 眼睛發炎
• 急性全身毒性
• 急性毒性試驗
• 用於急性毒性測試的細胞毒性測定
• 慢性和多次投藥毒性
• 致癌性和遺傳毒性
• 概述
• 體外方法：背景與最新進展
• 監理備案及藥物開發備案
• 減少誤報的舉措
• 篩檢的最新創新
• 未來的挑戰：非基因毒性致癌物
• 生殖和發育毒性
• 背景
• 生殖週期
• 發育和生殖毒性測試的類型
• 用於發育毒性篩檢的斑馬魚模型
• 斑馬魚與幹細胞的結合
• 生物醫學前沿：男性睪丸
• 篩檢內分泌干擾物
• 背景
• 環境毒理學對體外方法的影響
• ToxCast 和 Tox 21 計劃
• 未來的挑戰：甲狀腺破壞
• BG1檢測
• 毒物動力學和ADME
• 體外發育
• 代謝
• 低週轉化合物的藥物動力學
• 器官型模型
• 皮膚 3D 模型
• 3D角膜系統
• 吸收勢壘模型
• 胃
• 肺
• 血腦障壁
• 3D 組織屏障和細胞外基質的實際架構
• 肝毒性
• 肝臟的特異性和複雜性
• 肝臟是 3D 創新的關鍵
• 體外肝臟應用
• 體內肝功能和結構
• 肝臟代謝
• 體外肝臟模型
• 肝細胞和巨噬細胞的共培養
• 3D肝臟模型
• 生物列印肝組織
• 檢測到的肝球的結構和功能
• 理想標準
• 抗藥性
• 轉運蛋白研究
• 實現異型性細胞間接觸
• 未滿足的需求和未來創新的驅動力
• 形態發生素訊號傳導
• 多供體肝細胞
• 在腎毒性的應用
• 未來的挑戰：幹細胞衍生的腎臟細胞
• 生物列印腎臟組織
• 胰臟毒理學的應用
• 心血管毒性
• 商業化歷程
• 與監管機構的合作
• 心血管藥物研發
• 基於電阻的微電極陣列（MEA）
• 替代生物列印磁性分離主動脈環檢測
• 血管舒張活性
• 3D人工心臟組織

第9章區域市場細分

• 北美洲
• 美國
• 加拿大
• 歐洲
• 德國
• 英國
• 亞太地區
• 中國
• 日本
• 印度
• 韓國
• 新加坡
• 其他地區

第10章幹細胞的形勢

• 幹細胞的歷史
• 幹細胞主要研究領域
• 3D幹細胞培養系統
• 板或培養皿
• 槳鼻罩燒瓶和旋轉壁容器
• 灌註生物反應器和微載體系統
• 壞處
• 微流體和幹細胞
• 幹細胞生物學的簡短回顧
• 胚胎發育
• 幹細胞增生、結構與型態
• 幹細胞分化
• 幹細胞分化和增殖
• 細胞外基質和幹細胞
• 可溶性因子
• 幹細胞製造
• 胚胎樣體形成的控制
• 強迫集體文化
• 懸滴法
• 目的
• 用於高通量篩檢的幹細胞標記物
• 畸胎瘤和畸胎瘤檢測
• FUJIFILM（Cellular Dynamics Inc.）
• 幹細胞研究的突破性進展
• 用於神經科學發現和發展的幹細胞
• 例：阿茲海默症研究
• 背景：B-澱粉連鎖假說
• 人類 iPS 細胞衍生模型
• 新的 3D 模型
• 3D 的其他好處
• 預期用途
• 其他 3D 神經應用
• 幹細胞用於心血管發現
• 用於再生醫學開發的幹細胞
• 背景：同種異體與自體同體
• 微小RNA
• 誘導性多功能幹細胞（IPS）

第11章再生醫學：器官移植與皮膚替代

• 再生醫學
• 需要器官移植
• 再生醫學中的應用
• 再生醫學投資
• 皮膚替代品產業
• 組織培養同種異體移植及自體移植產品
• 再生醫學中的組織工程

第12章 公司簡介

• 3D BIOPRINTING SOLUTIONS
• 3D BIOTEK LLC
• 4D TECHNOLOGY CORP.
• ABCAM PLC
• AKRON BIOTECH
• AGILENT TECHNOLOGIES INC.
• ALPCO
• AMSBIO
• BECKMAN COULTER INC.
• BIOINSPIRED SOLUTIONS
• BIOTIME INC.
• BIOVISION INC.
• CELL APPLICATIONS INC.
• CELLINK
• CORNING INC.
• CYPROTEX
• CYTIVA
• CYTOO SA
• EMD MILLIPORE/MERCK KGAA
• EMULATE INC.
• ENVISIONTEC INC.
• EPITHELIX
• EUROFINS SAS
• GREINER BIO-ONE INTERNATIONAL GMBH
• HAMILTON ROBOTICS
• HUB ORGANOIDS
• HUREL CORP.
• INSPHERO
• INVITROCUE
• KIYATEC INC.
• LIFENET HEALTH
• LOREM VASCULAR/CYTORI THERAPEUTICS INC.
• MATTEK
• MIMETAS INC.
• ORGANOVO HOLDINGS INC.
• PERKINELMER INC.
• PLASTICELL LTD.
• PLURISTEM THERAPEUTICS INC.
• POIETIS
• PROMEGA CORP.
• SEAHORSE BIOSCIENCE
• STEMCELL TECHNOLOGIES
• STRATATECH CORP.
• SYNVIVO INC.
• TAP BIOSYSTEMS
• TECAN TRADING AG
• ZEN-BIO INC.

Highlights:

The global market for 3D cell culture is estimated to increase from $4.6 billion in 2023 to reach $14.8 billion by 2028, at a compound annual growth rate (CAGR) of 26.5% from 2023 through 2028.

The global market for 3D cell culture for research segment is estimated to increase from $2.3 billion in 2023 to reach $7.8 billion by 2028, at a CAGR of 27.3% from 2023 through 2028.

The global market for 3D cell culture for bioprocessing segment is estimated to increase from $2.2 billion in 2023 to reach nearly $7.0 billion by 2028, at a CAGR of 25.7% from 2023 through 2028.

Report Scope:

This report aims to provide a comprehensive study of the global 3D cell culture technologies market. It provides a detailed description of the different types of healthcare interoperability solutions and their current and historical market revenues.

The scope of the report encompasses the major types of 3D cell culture which are being used by industry, academic researchers, government labs, and independent research groups. This includes the main inputs such as cell lines, media, sera, reagents, software, and instrumentation. It analyzes the current market status, examines future market drivers and presents forecasts of growth over the next five years.

The market structure has been reorganized for this edition. Also, more research was done on base case data for different product areas. The greater emphasis is on the different products used for 3D cell culture, but the report also investigates the market in terms of types of applications, end users and geographic regions.

Report Includes:

• 17 data tables and 105 additional tables
• An overview of the global market landscape related to the 3D cell cultures technologies
• In-depth analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, as well as forecasts for 2028. This analysis includes projections of Compound Annual Growth Rates (CAGRs) spanning through 2028
• Evaluation of the current market size and revenue growth prospects specific to 3D cell cultures technologies, accompanied by a comprehensive market share analysis categorized by type, end user, and geographical region
• Information on analytical systems used in tissue and cell culture, cellomics, and human cancer model initiative (HCMI)
• Details about assay development for mesenchymal stem cells, In Vitro testing of adventitious agents and description of assays and assay kits
• A look at the main classes of models for researching cancer and other diseases, benefits of 3D models to cancer research and description of 3D engineered scaffolds
• Analysis of the market's dynamics, specifically growth drivers, restraints, and opportunities and discussion on the impact of COVID-19 on the world of cell culture
• Insights into U.S. regulatory status of bioprinted products; basic guidance for the regulation of biologics, regenerative medicine and xenotransplants
• Relevant patent analysis, including recent activity and a list of key patents
• Detailed profiles of leading market participants, providing a descriptive overview of their respective businesses, including Abcam PLC, Agilent Technologies Inc., Corning Inc., Merck KGAA, Beckman Coulter, and Synvivo Inc.

Table of Contents

Chapter 1 Introduction

• Study Goals and Objectives
• Reasons for Doing the Study
• Scope of Report
• What's New in This Report?
• Methodology and Information Sources
• Geographic Breakdown
• Segment Breakdown

Chapter 2 Summary and Highlights

• Market Outlook
• Market Summary

Chapter 3 Market Overview

• An Opening Comment on an Amazing Industry
• Industry Issues
• In Vitro versus In Vivo
• Dimensionality
• The Research Chain for 2D and 3D Cell Culture
• Best Practices
• Standardization
• Regulation
• Genomics Forcing the Hand of the FDA
• Leachables and Extractables
• Broad Issues
• Research Talent Shortages
• The Shifting International Picture
• Pace and Diversification of Innovation
• A Comment on the "Other" Areas of Cell Culture
• Omics Everywhere
• Is 2020 a Watershed Year for the Cell Culture Industry?
• Preliminary Market Analysis
• Cell Culture Market Growth Rate Estimates
• Assessing Large-Scale Media Consumption Needs
• Modeling Future Growth in Biopharmaceuticals
• Base Case for the Cell Culture Market
• Challenges in Projecting Sales and Growth
• Cell Culture Media Market Estimates
• Cell and Gene Therapy Bioprocessing Segment
• Evaluating Media Consumption for Biosimilars
• What About CDMOs?
• Microfluidics
• Bioreactors
• Internal Cell Culture Resources
• Is There Too Much Concentration of Ownership in Biotechnology?
• Characterizing Innovation in 3D Cell Culture
• Bioprinting Strategic Roadmap

Chapter 4 Market, by Type

• Where Did Tissue and Cell Culture Start?
• History and Early Applications
• Invention of Tissue Culture
• Development of Sustained Cell Lines
• First Cell Culture Flask and Rigorous Techniques
• Lindbergh: The Cell Culture Equipment Pioneer
• Establishing Continuous Cell Lines
• Key Developments in Equipment
• Terminology and Concepts
• Tissue and Cell Culture Industry
• Tissue Culture and Cell Culture Definitions
• Cell Lines
• Care and Growth of Cell Culture Systems
• Media, Sera, and Reagents
• Gels and Scaffolds
• Microplates/Microtiter Plates
• Bioanalytical Instruments
• Bioanalytical Imaging
• Bioprinting
• Bioreactors
• Other Equipment for Cell Culture
• Adherent Approaches
• Traditional Roller Bottles
• Other Systems
• Information Technology: Software and Services for the Cell Culture Research Market
• Software for the Research Market in Cell Culture
• Software-Related Support Services
• Bioprocessing Consumables for Cell Culture
• Microcarriers for Large-Scale 3D Culture
• Sera for Large-Scale 3D Culture
• Media for Large-Scale 3D Culture
• Bioreactor Bags for Large-Scale 3D Culture
• Other
• Bioprocessing Equipment
• Analytical Equipment for Bioprocessing
• Automation Systems for Bioprocessing
• Support Equipment for Bioprocessing
• Aspects of Large-Scale Manufacturing of Biopharmaceuticals and Vaccines
• Suspension Proteins and Monoclonal Antibodies
• Adherent-Cell-Based Therapies and Vaccines
• Small-Scale Adherent to Make Somatic Cells, Stem Cells and Tissues
• Vaccines
• Vaccine Development as a Catalyst
• Vaccines Developed Using Human Cell Strains
• Exosome Manufacturing
• Viral Vector Manufacturing
• Lentivirus Manufacturing
• Plasmid Manufacturing
• Cell Culture End Users
• Pharma/Biopharma
• Universities
• Government
• CROs/CDMOS
• Other
• Cell Culture Applications
• Drug Discovery
• Clinical Development
• Toxicology
• Basic Research
• Bioprocessing Development
• Other
• Regional Markets
• The Americas
• Europe
• Asia-Pacific
• Rest of the World

Chapter 5 Assays, Imaging and Analysis

• Assays
• Assay Development for Mesenchymal Stem Cells
• In Vitro Testing of Adventitious Agents
• Assays and Assay Kits
• Cell-Based Assays: Overview and Newer Developments
• Cells Used in Cell-Based Assays
• Notes on 3D Cell-Based Assays
• Kinetic Metabolism Assays
• Cell Proliferation
• Viability and Cytotoxicity
• Permeability Assays for Cell Viability and Survival
• Cell Invasion
• Cell Signaling and Communication
• Cytostatic
• Cell Death Assays
• Imaging Technology
• Imaging Assays
• Fluorescence as a Driver of Screening
• Analytical Systems Used in Tissue and Cell Culture
• Understanding "Cellomics"
• HCS Support of 3D Cell Culture
• NGS Discovery Pools
• Multiplex Assays
• Predictive Toxicology
• Neuro Safety
• The Omics Invasion
• Transcriptomics

Chapter 6 Regulation and Standardization

• U.S. Regulatory Status of Bioprinted Products
• Basic Guidance for the Regulation of Biologics
• Guidance for Regenerative Medicine
• Guidance for Xenotransplants
• Guidance for Regenerative Medicine: Emergency Approval
• Regulating Bioprinted Products

Chapter 7 3D Models for Cancer

• Disease Modeling
• Cancer
• Main Classes of Models for Researching Cancer and Other Diseases
• Cell Lines
• Spheroids and Organoids
• Genetically Engineered Mouse Model (GEMM)
• Patient-Derived Tumor Xenografts (PDXs)
• Overview: Cancer at the Cellular Level
• In Vivo (Animal) Testing Standard
• Empire of the Mouse
• Humanized Mice
• 2D Culture
• 3D Requirements
• Cell Number and Viability
• Migration and Invasion
• Unmet Needs: Angiogenesis and Immune System Evasion
• Benefits of 3D Models to Cancer Research
• Greater Distinction in Cell Morphology and Proliferation
• Greater Gene Expression and Cell Behavior
• Better Models of Cell Migration and Invasion
• Cell Heterogeneity
• Breast Cancer as a Driver of 3D Cultures
• Structure, Polarity and Apoptosis
• Melanoma as a Driver of 3D Cultures
• Moving to Spheroid Configurations
• 3D Systems in Cancer Research
• Multicellular Tumor Spheroids
• Multilayered Cell Cultures
• 3D Engineered Scaffolds
• Natural Materials
• Synthetic Materials
• Human Cancer Model Initiative (HCMI)
• Next-Generation Human Cancer Models
• Drug Sensitivity and Resistance
• Altered Signaling and Sensitivity
• Drug Resistance
• Cellular Signaling
• Cellular Signaling Mediated by Integrins
• Drug Screening
• Approaches and Endpoints
• Spheroid Applications
• Metastasis via 3D Cell Migration Model
• Metastasis via Lung-on-Chip
• Cancer Metabolism
• Future Horizons
• Metastases
• Co-culture
• Vascularization
• Cancer-Associated Fibroblasts
• Cancer Stem Cells
• Combination Therapies
• Biologics Development
• Tumor Recurrence
• Patient-Derived Cells
• Patient-Derived Tumor Xenografts (PDXs)
• Evolution of PDX Platforms

Chapter 8 Landscape for Toxicology and Drug Safety Testing

• Introduction
• Liver
• Toxicology Background
• Testing for Adverse Effects on the Skin
• New Assessment Methodologies Impact on 3D Cell Culture
• Toxicology Testing in Cosmetics
• Updated Regulatory Requirements
• Efficacy of Cosmetics and Cosmeceuticals
• Aspects of Cosmetic Toxicity Testing
• Skin Irritation
• Skin Corrosion
• Phototoxicity
• Skin Sensitization
• Eye Irritation
• Acute Systemic Toxicity
• Acute Toxicity Testing
• Cytotoxicity Assays for Acute Toxicity Testing
• Chronic and Repeated Dose Toxicity
• Carcinogenicity and Genotoxicity
• Overview
• In Vitro Methods: Background and Recent Developments
• Regulatory versus Drug Development Applications
• Efforts to Reduce False Positives
• Recent Innovations in Screening
• Future Challenge: Non-genotoxic Carcinogens
• Reproductive and Developmental Toxicity
• Background
• Following the Reproductive Cycle
• Development and Reproductive Tox Testing Types
• Zebrafish Model for Developmental Toxicity Screening
• Combination of Zebrafish and Stem Cells
• Biomedical Frontiers: Male Testis
• Endocrine Disruptor Screening
• Background
• Environmental Toxicology Impacts In Vitro Methods
• ToxCast and Tox 21 Initiatives
• Future Challenge: Thyroid Disruption
• BG1 Assay
• Toxicokinetics and ADME
• In Vitro Developments
• Metabolism
• Pharmacokinetics of Low-Turnover Compounds
• Organotypic Models
• 3D Models for Skin
• 3D Corneal System
• Absorption Barrier Models
• Gastrointestinal
• Lung
• Blood-Brain Barrier
• Real Architecture for 3D Tissue Barriers and Extracellular Matrix
• Liver Toxicity
• Uniqueness and Complexity of Liver
• Liver as a Key Driver for 3D Innovation
• In Vitro Liver Applications
• In Vivo Liver Function and Structure
• Liver Metabolism
• In Vitro Liver Models
• Co-cultures of Hepatocytes and Macrophages
• 3D Liver Models
• Bioprinted Liver Tissue
• Detected Hepatosphere Structures and Functionality
• Ideal Criteria
• Drug Resistance
• Transporter Studies
• Achieving Heterotypic Cell-Cell Contacts
• Unmet Needs and Future Drivers of Innovation
• Morphogen Signaling
• Multi-donor Liver Cells
• Kidney Toxicity Applications
• Future Challenge: Stem-Cell Derived Kidney Cells
• Bioprinted Kidney Tissue
• Pancreatic Toxicology Applications
• Cardiovascular Toxicity
• Commercial Avenue
• Collaboration with Regulators
• Cardiovascular Drug Discovery
• Microelectrode Arrays (MEAs) Based on Impedance
• Surrogate for Aortic Ring Assay via Bioprinted Magnetics
• Vasodilator Activity
• 3D Engineered Heart Tissues

Chapter 9 Market Breakdown by Region

• Introduction
• North America
• United States
• Canada
• Europe
• Germany
• United Kingdom
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Singapore
• Rest of the World

Chapter 10 Stem Cell Landscape

• A History of Stem Cells
• Major and Minor Research Areas for Stem Cells
• 3D Stem Cell Culture Systems
• Plate or Culture Dish
• Spinner Flask and Rotating Wall Vessel
• Perfusion Bioreactor and Microcarrier Systems
• Shortcomings
• Microfluidics and Stem Cells
• Short Review of Stem Cell Biology
• Embryogenesis
• Growth, Structure and Morphology of Stem Cells
• Stem Cell Differentiation
• Stem Cell Differentiation versus Proliferation
• Extracellular Matrix and Stem Cells
• Soluble Factors
• Manufacturing Stem Cells
• Controlling Embryoid Body Formation
• Forced Aggregation Cultures
• Hanging-Drop Approach
• Applications
• Stem Cell Markers for High-Throughput Screening
• Teratomas and the Teratoma Assay
• Fujifilm (Cellular Dynamics Inc.)
• Stem Cell Research Breakthroughs
• Stem Cells for Neuroscience Discovery and Development
• Example: Alzheimer's Research
• Background: B-Amyloid Cascade Hypothesis
• Human iPSC-Derived Models
• New 3D Model
• Other Advantages of 3D
• Envisioned Applications
• Other 3D Neuro Applications
• Stem Cells for Cardiovascular Discovery
• Stem Cells for the Development of Regenerative Medicine
• Background: Allogenic versus Autologous
• MicroRNAs
• Induced Pluripotent Stem Cells (IPS)

Chapter 11 Regenerative Medicine: Organ Transplants and Skin Substitutes

• Regenerative Medicine
• Need for Organ Transplants
• Applications in Regenerative Medicine
• Investments in Regenerative Medicine
• Skin Substitutes Industry
• Tissue Culture Allograft and Autograft Products
• Tissue Engineering in Regenerative Medicine

Chapter 12 Company Profiles

• 3D BIOPRINTING SOLUTIONS
• 3D BIOTEK LLC
• 4D TECHNOLOGY CORP.
• ABCAM PLC
• AKRON BIOTECH
• AGILENT TECHNOLOGIES INC.
• ALPCO
• AMSBIO
• BECKMAN COULTER INC.
• BIOINSPIRED SOLUTIONS
• BIOTIME INC.
• BIOVISION INC.
• CELL APPLICATIONS INC.
• CELLINK
• CORNING INC.
• CYPROTEX
• CYTIVA
• CYTOO SA
• EMD MILLIPORE / MERCK KGAA
• EMULATE INC.
• ENVISIONTEC INC.
• EPITHELIX
• EUROFINS SAS
• GREINER BIO-ONE INTERNATIONAL GMBH
• HAMILTON ROBOTICS
• HUB ORGANOIDS
• HUREL CORP.
• INSPHERO
• INVITROCUE
• KIYATEC INC.
• LIFENET HEALTH
• LOREM VASCULAR / CYTORI THERAPEUTICS INC.
• MATTEK
• MIMETAS INC.
• ORGANOVO HOLDINGS INC.
• PERKINELMER INC.
• PLASTICELL LTD.
• PLURISTEM THERAPEUTICS INC.
• POIETIS
• PROMEGA CORP.
• SEAHORSE BIOSCIENCE
• STEMCELL TECHNOLOGIES
• STRATATECH CORP.
• SYNVIVO INC.
• TAP BIOSYSTEMS
• TECAN TRADING AG
• ZEN-BIO INC.

List of Tables

• Summary Table : Global Market for 3D Cell Culture, by Segment, Through 2028
• Table 1 : Dimensionality of Cell Culture
• Table 2 : WHO R&D Roadmap of Priority Infectious Diseases
• Table 3 : 3D Bioprinting Roadmap
• Table 4 : Selected Online Prices for Bioreactors
• Table 5 : Global Market for 3D Cell Culture, by Segment, Through 2028
• Table 6 : Tissue Types
• Table 7 : Cell Types Based on Developmental Origin
• Table 8 : Leading Cell Line Suppliers, April 2020
• Table 9 : Commonly Used Transformed Cells Lines
• Table 10 : Major Primary Cell Lines
• Table 11 : Leading Primary Cell Suppliers
• Table 12 : Main Types of Stem Cells
• Table 13 : Stem Cell Services
• Table 14 : Areas of Interest in 3D Spheroid Research
• Table 15 : Selected Nanoparticle Products Used in Life Science Research
• Table 16 : Results of Liver-Chip Drugs Halted in Previous Clinical Trials Based on Animal Studies
• Table 17 : Companies and Universities Involved in the Organ-on-a-Chip Industry
• Table 18 : Microfluidics Companies
• Table 19 : Selected Recent Patents Issued on Microfluidic Devices Related to Cell Culture Applications
• Table 20 : Selected Papers Published on Recent Microfluidic Advances in Cell Culture
• Table 21 : High-Content Screening Suppliers and Key Attributes
• Table 22 : Selected Patents Issued Related to Flow Cytometers
• Table 23 : Thermo Fisher Imaging Products
• Table 24 : Recent Bioprinting Company Deals and Strategic Partnerships
• Table 25 : Bioprinting Modalities
• Table 26 : Maintaining Cell Viability During Printing
• Table 27 : Bioprinting Instrument Industry
• Table 28 : Biomaterial Components
• Table 29 : Bioink Types
• Table 30 : Classes of Matrix Bioink Hydrogels
• Table 31 : Matrix Bioink Selection Criteria
• Table 32 : Selected Bioink Companies, 2020
• Table 33 : Projected Unit Sales of Research Bioreactors, <10 Liters, 2020
• Table 34 : Leading Bioreactor Suppliers, 2020
• Table 35 : Label-Free Technologies and Suppliers
• Table 36 : Developmental Issues Facing the Commercialization of Exosomes
• Table 37 : Companies Working on Exosome Products
• Table 38 : Global Market for Cell Culture, by End User, Through 2028
• Table 39 : Global Market for Cell Culture, by Application, Through 2028
• Table 40 : Global Market for Cell Culture, by Region, Through 2028
• Table 41 : Typical Assay Endpoints and Tests
• Table 42 : U.S. Patents on Assays Systems, 2019 and 2020
• Table 43 : Selected U.S. Patents on Assay Imaging, 2019 and 2020
• Table 44 : Recently Issued U.S. Patents on Cellomics, 2019
• Table 45 : Toxicology Issues That Need to Be Addressed for FDA-Regulated Products
• Table 46 : Overview of Federal Regulation of the Cell Culture Markets
• Table 47 : FDA List of Cell, Biologic and Tissue Products Regulated Under CBER and CDRH
• Table 48 : FDA "Talking Point" Recommendations for Regenerative Medicine Advanced Therapies (RMATs)
• Table 49 : U.S. Regulatory Considerations for Bioprinted Biologics
• Table 50 : Main Types of Models for Researching Cancer and Other Diseases
• Table 51 : Goals of Funding Opportunity Announcement RFA-CA-19-055
• Table 52 : Common 3D Assays
• Table 53 : Summary of the Benefits and Advantages of EV3D
• Table 54 : ECVAM List of Current Activities, 2020
• Table 55 : In Vitro Testing in Cosmetics, by Test Class
• Table 56 : Global Market for Cell Culture by Region, Through 2028
• Table 57 : North American Market for Cell Culture by Country, Through 2028
• Table 58 : European Market for Cell Culture by Country, Through 2028
• Table 59 : Asia-Pacific Market for Cell Culture by Country, Through 2028
• Table 60 : RoW Market for Cell Culture by Region, Through 2028
• Table 61 : Major and Minor Research Areas in Stem Cells
• Table 62 : Stem Cell Usage in Research
• Table 63 : Recent U.S. Patents Granted on Stem Cell Technologies
• Table 64 : Papers Published on Selected Stem Cell Research Trends
• Table 65 : Comparison of the Number of Citations in the Literature on Cell Culture versus Stem Cell Culture
• Table 66 : Number of Organ Transplants Performed in the United States, 2018 and 2019
• Table 67 : Total Global Financing of Regenerative Medicine
• Table 68 : Total Financing of Regenerative Medicine, by Therapeutic Area
• Table 69 : Leading Tissue Products and Suppliers
• Table 70 : Printed Tissue and Organs: Commercialization Timeframe
• Table 71 : Tissue/Organ Complexity
• Table 72 : 3D Bioprinting Solutions: Company Snapshot
• Table 73 : 3D Biotek LLC: Company Snapshot
• Table 74 : 4D Technology Corp.: Company Snapshot
• Table 75 : Abcam Plc: Company Snapshot
• Table 76 : Abcam PLC: Financial Performance, 2022
• Table 77 : Akron Biotech: Company Snapshot
• Table 78 : Agilent Technologies: Company Snapshot
• Table 79 : Agilent Technologies Inc.: Financial Performance, 2022
• Table 80 : Alpco: Company Snapshot
• Table 81 : Amsbio: Company Snapshot
• Table 82 : Beckman Coulter: Company Snapshot
• Table 83 : Bioinspired Solutions: Company Snapshot
• Table 84 : BioTime Inc.: Company Snapshot
• Table 85 : Biovision Inc.: Company Snapshot
• Table 86 : Cell Applications Inc.: Company Snapshot
• Table 87 : Cellink: Company Snapshot
• Table 88 : Corning Inc.: Company Snapshot
• Table 89 : Corning Inc.: Financial Performance, 2022
• Table 90 : Cyprotex: Company Snapshot
• Table 91 : Cytiva: Company Snapshot
• Table 92 : Cytoo SA: Company Snapshot
• Table 93 : Merck KGAA: Company Snapshot
• Table 94 : Merck KGAA: Financial Performance, 2022
• Table 95 : Emulate Inc.: Company Snapshot
• Table 96 : EnvisionTec Inc.: Company Snapshot
• Table 97 : Epithelix: Company Snapshot
• Table 98 : Greiner Bio-One International GmbH: Company Snapshot
• Table 99 : Hamilton Robotics: Company Snapshot
• Table 100 : HUB Organoids: Company Snapshot
• Table 101 : Hurel Corp.: Company Snapshot
• Table 102 : Insphero: Company Snapshot
• Table 103 : Invitrocue: Company Snapshot
• Table 104 : Kiyatec Inc.: Company Snapshot
• Table 105 : LifeNet Health: Company Snapshot
• Table 106 : Cytori Therapeutics Inc.: Company Snapshot
• Table 107 : Mattek: Company Snapshot
• Table 108 : Mimetas Inc.: Company Snapshot
• Table 109 : Organovo Holdings Inc.: Company Snapshot
• Table 110 : PerkinElmer Inc.: Company Snapshot
• Table 111 : Plasticell Ltd.: Company Snapshot
• Table 112 : Pluristem Therapeutics Inc.: Company Snapshot
• Table 113 : Poietis: Company Snapshot
• Table 114 : Promega Corp.: Company Snapshot
• Table 115 : SeaHorse Bioscience: Company Snapshot
• Table 116 : Stemcell Technologies: Company Snapshot
• Table 117 : Stratatech Corp.: Company Snapshot
• Table 118 : Synvivo Inc.: Company Snapshot
• Table 119 : Tap Biosystems: Company Snapshot
• Table 120 : Tecan Trading AG: Company Snapshot
• Table 121 : Zen-Bio Inc.: Company Snapshot

List of Figures

• Summary Figure : Global Market for 3D Cell Culture, by Segment, 2020-2028
• Figure 1 : Research Chain for Cell Culture
• Figure 2 : A Model for The Evolution of FDA Regulation
• Figure 3 : 3D Cell Cultures: Market Dynamics
• Figure 4 : An Innovation Matrix
• Figure 5 : Bioprinting Strategic Roadmap
• Figure 6 : Global Market Shares of 3D Cell Culture, by Segment, 2022
• Figure 7 : Gastrointestinal Organotype Cultures
• Figure 8 : iCELLis Nanoreactor: Example of Commercial 2D Cell Culture Systems
• Figure 9 : Prototype of 3D Model Lung-on-a-Chip from Wake Forest
• Figure 10 : Recent Photo of the HepaChip
• Figure 11 : Recent Photo of the HepaChip-MWP
• Figure 12 : University of Toronto Handheld Bioprinting Device
• Figure 13 : Collaborative Experiment Conducted by American, Russian and Israeli Scientists
• Figure 14 : Smart Marbles Concept for Quantifying Process Heterogeneity
• Figure 15 : Porcine Intestinal Organoids
• Figure 16 : Diagram of the Components of a Predictive Toxicology System
• Figure 17 : Gleason's Pattern
• Figure 18 : Diagram of PDXs, Cell Lines and Organoid/Spheroid Xenografts
• Figure 19 : Cell Heterogeneity and Its Function
• Figure 20 : Global Market for Cell Culture by Region, 2020-2028
• Figure 21 : North American Market for Cell Culture by Country, 2020-2028
• Figure 22 : European Market for Cell Culture by Country, 2020-2028
• Figure 23 : Asia-Pacific Market for Cell Culture by Country, 2020-2028
• Figure 24 : ROW Market for Cell Culture by Region, 2020-2028
• Figure 25 : Electron Micrograph of Porous Microcarrier for Stem Cell Production
• Figure 26 : Photograph of Apligraf
• Figure 27 : Abcam PLC: Financial Performance, 2021 and 2022
• Figure 28 : Abcam PLC: Revenue Shares, by Country/Region, 2022
• Figure 29 : Agilent Technologies Inc.: Financial Performance, 2021 and 2022
• Figure 30 : Agilent Technologies Inc.: Revenue Shares, by Business Unit, 2022
• Figure 31 : Agilent Technologies Inc.: Revenue Shares, by Country/Region, 2022
• Figure 32 : Corning Inc.: Revenue Shares, by Business Unit, FY 2022
• Figure 33 : Corning Inc.: Revenue Shares, by Region, FY 2022
• Figure 34 : Merck KGAA: Revenue Shares, by Business Unit, FY 2022
• Figure 35 : Merck KGAA: Revenue Shares, by Region, FY 2022